TY  - JOUR
AU  - Hatem, Reem
AU  - Nawaz, Faisal A
AU  - Al-Sharif, Ghadah A
AU  - Almoosa, Mohammad
AU  - Kattan, Wid
AU  - Tzivinikos, Christos
AU  - Amirali, E Lila
AU  - Albanna, Ammar
PY  - 2022
DA  - 2022/3/21
TI  - Nonalcoholic Fatty Liver Disease in Children and Adolescents Taking Atypical Antipsychotic Medications: Protocol for a Systematic Review and Meta-analysis
JO  - JMIR Res Protoc
SP  - e20168
VL  - 11
IS  - 3
KW  - nonalcoholic fatty liver disease
KW  - psychopharmacology
KW  - antipsychotics
KW  - children
KW  - adolescents
KW  - overprescribing
KW  - pharmaceuticals
KW  - antipsychotic medications
KW  - medication
KW  - pediatric psychopharmacology
KW  - pharmacology
KW  - child and adolescent psychiatry
AB  - Background: Atypical antipsychotics (AAP) are commonly prescribed to children and adolescents and are associated with important adverse effects including weight gain and metabolic syndrome. Nonalcoholic fatty liver disease (NAFLD) is not only the most common pediatric liver disease but is also associated with serious complications including liver cirrhosis. Objective: Given that NAFLD and AAP are associated with metabolic syndrome, we aim to comprehensively examine the association between AAP and NAFLD in children and adolescents. Methods: We will conduct a systematic review of studies exploring NAFLD in subjects younger than 18 years on AAP published in English between 1950 and 2020 following the PRISMA (Preferred Reporting items for Systematic Reviews and Meta-Analysis) guidelines. Results: A PRISMA flowchart will be used present the study results after comprehensively reviewing studies on NAFLD in children and adolescents taking AAP. The first and second systematic searches will be conducted during December 2021. The results are expected to be published in June 2022. Conclusions: This research project will serve as a foundation for future studies and assist in devising interventions and reforming clinical guidelines for using AAP to ensure improved patient safety. International Registered Report Identifier (IRRID): PRR1-10.2196/20168 
SN  - 1929-0748
UR  - https://www.researchprotocols.org/2022/3/e20168
UR  - https://doi.org/10.2196/20168
UR  - http://www.ncbi.nlm.nih.gov/pubmed/35311689
DO  - 10.2196/20168
ID  - info:doi/10.2196/20168
ER  -